View all studies | NASH - Advanced Fatty Liver

NASH Research Study

The hidden epidemic you need to know about.

NASH, short for Nonalcoholic Steatohepatitis, is an advanced nonalcoholic fatty liver disease characterized by a buildup of fat on the liver that can cause permanent damage hindering its ability to filter the blood. It’s estimated that 16 million Americans have been diagnosed with NASH, with many more likely undiagnosed. Currently, it’s the second leading cause of liver transplants in the US. A noninvasive liver FibroScan® (similar to an ultrasound) can be done to determine a probable diagnosis, but should be confirmed by a biopsy. Risk factors include: type 2 diabetes, high cholesterol, and obesity with an accumulation of fat around the midsection.

Right now, there are no medications currently approved for treating NASH. Accellacare is enrolling studies that may lead to the first approved treatment. Eligible participants will receive study-related care and study medication at no cost.

Submit to learn more:

Do you have a diagnosis of fatty liver disease? *

Yes

First Name *

Last Name *

DOB (month/day/year) *

Email Address *

Address (Town/City) *

Zip Code *

Phone Number (inc. area code)* *

**By registering and providing your telephone number, you agree to receive text messages from Accellacare for the purposes above at the number you provide. Message and data rates may apply. Message frequency will vary. No mobile information will be shared with third parties/affiliates for marketing/promotional purposes. For help, reply HELP to any message. To opt-out, reply STOP to any message.

Select your nearest clinic *

When you register your interest with Accellacare (which is part of ICON plc), our team will add your information to our database, review your information and connect you with studies that you may be eligible for. When we find a match, Accellacare clinical research specialists will contact you directly for further pre-screening by phone and may refer you on to Accellacare sites or collaborating third-party sites for further on-site pre-screening. We may also contact you in the future by phone call, text message, or email regarding future trials you may be interested in based on the information you provide to us. The clinic you choose in the registration form below may be a third-party study site (which will be clearly indicated) that collaborates with Accellacare on clinical trials. If you select a third-party site, you agree that we may share your personal data with that clinic for further pre-screening. That clinic will be independently responsible for processing your personal data in accordance with all applicable data protection laws.

Data Protection

ICON plc is responsible for the personal data, including data related to your health, race, and ethnicity you choose to provide. We rely on your consent to add your information to our database, use this information to identify potentially appropriate clinical studies for you and contact you about them. When we call you for further pre-screening, note that these calls will be recorded. If you have selected a third-party site, we will share your information with this site so they can contact you for further pre-screening.

You can withdraw your consent at any time, for example by following instructions to do so in emails or text messages you receive from us, or by telling our patient recruitment team when speaking with them. This does not affect the lawfulness of the processing prior to your withdrawal. Additional information on how your data will be processed and how you can exercise your rights, can be found in our Privacy Policy. Please confirm if you consent to ICON plc collecting, using and sharing your personal data for the above purposes. *

I Agree

Please enter the security code:

Please note: You may or may not benefit medically from taking part and you are able to opt out at anytime and do not have to give us a reason for doing so. Your primary care physician will be informed about your participation and all medical assessments that will be carried out as part of the study. If during screening any abnormal results are found your primary care physician will also be informed.